青春前期女性接种人乳头瘤病毒疫苗专家共识

doi:10.12183/j.scjpm.2021.1155

摘要/Abstract

摘要： 人乳头瘤病毒（HPV）疫苗接种是子宫颈癌防控的重要措施之一。通过综合考虑HPV疫苗接种的有效性、安全性、成本效益等多方面因素,专家强烈推荐青春前期（9~14岁）女性作为重点目标人群应优先接种HPV疫苗,提高重点目标人群HPV疫苗免疫覆盖率,以达到子宫颈癌一级预防策略的最佳效果。

关键词: 青春前期, 人乳头瘤病毒, 疫苗, 子宫颈癌

Abstract: Human papillomavirus （HPV） vaccination is one of the essential measures for cervical cancer prevention and control. By comprehensively analyzing the effectiveness, safety, cost-effectiveness and other factors of HPV vaccination, experts strongly recommend prepubertal girls （9~14 years old） as the primary target population,and HPV vaccines should be given priority to them. Improving the vaccination coverage among target populations can achieve the best effect of the primary prevention strategy of cervical cancer.

Key words: Prepuberty, Human papillomavirus, Vaccines, Cervical cancer

中图分类号:

R186

李小毛, 李依芬, 万璟, 杨越波, 张宇. 青春前期女性接种人乳头瘤病毒疫苗专家共识[J]. 华南预防医学, 2021, 47(9): 1155-1161.

LI Xiao-mao, LI Yi-fen, WAN Jing, YANG Yue-bo, ZHANG Yu. Expert consensus on human papillomavirus vaccination for prepubertal girls[J]. South China Journal of Preventive Medicine, 2021, 47(9): 1155-1161.

参考文献

[1] Gultekin M, Ramirez PT, Broutet N, et al.World Health Organization call for action to eliminate cervical cancer globally[J]. Int J Gynecol Cancer,2020,30(4): 426-427.
[2] Zhu B, Liu Y, Zuo T, et al.The prevalence, trends, and geographical distribution of human papillomavirus infection in China: The pooled analysis of 1.7 million women[J].Cancer Med,2019,8(11):5373-5385.
[3] Wang R, Guo X, Wisman GBA, et al.Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China[J]. BMC Infect Dis,2015,15(1):257.
[4] Secor-Turner M, Kugler K, Bearinger LH, et al.A global perspective of adolescent sexual and reproductive health: context matters[J]. Adolescent Medicine (Elk Grove Village, Ill.),2009,20(3):1005.
[5] 国家卫生计生委家庭司. 中国家庭发展报告2015[M]. 北京:中国人口出版社,2015:83-84.
[6] Shu C, Fu A, Lu J, et al.Association between age at first sexual intercourse and knowledge, attitudes and practices regarding reproductive health and unplanned pregnancy: A cross-sectional study[J]. Public Health,2016,135:104-113.
[7] Vinodhini K, Shanmughapriya S, Das BC, et al.Prevalence and risk factors of HPV infection among women from various provinces of the world[J]. Arch Gynecol Obstet,2012,285(3):771-777.
[8] Patel A, Galaal K, Burnley C, et al.Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study[J]. Br J Cancer,2012,106(11):1753-1759.
[9] 孟令昊,胥秋艳,李科,等. 1990—2019年中国女性宫颈癌疾病负担变化的分析[J]. 中国循证医学杂志,2021,21(6):648-653.
[10] Li X, Zheng R, Li X, et al.Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014[J]. Chin J Cancer Res,2017,29(6):477-486.
[11] Cai HB, Liu XM, Huang Y, et al.Trends in cervical cancer in young women in Hubei, China[J]. Int J Gynecol Cancer,2010,20(7):1240-1243.
[12] WHO. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine,2017,35(43):5753-5755.
[13] No authors listed.Human papillomavirus vaccination: ACOG committee opinion summary, Number 809[J]. Obstet Gynecol,2020,136(2):435-436.
[14] Xia C, Xu X, Zhao X, et al.Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: A modeling study[J]. BMC Med,2021,19(1):62.
[15] Hu Y, Guo M, Li C, et al.Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs.3 doses in young women[J]. Sci China Life Sci,2020,63(4):582-591.
[16] Zhu F, Li J, Hu Y, et al.Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J]. Hum Vaccin Immunother,2014,10(7):1795-1806.
[17] Puthanakit T, Huang LM, Chiu CH, et al.Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years[J]. J Infect Dis,2016,214(4):525-536.
[18] Li R, Li Y, Radley D, et al.Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females[J]. Vaccine,2012,30(28):4284-4291.
[19] Dobson SR, Mcneil S, Dionne M, et al.Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial[J]. JAMA,2013,309(17):1793-1802.
[20] Iversen O, Miranda MJ, Ulied A, et al.Immunogenicity of the 9-valent HPV vaccine using 2-Dose regimens in girls and boys vs a 3-dose regimen in women[J]. JAMA,2016,316(22):412-413.
[21] Mélanie D, élodie B, Norma P, et al.Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis[J]. Lancet,2019,394(10197):497-509.
[22] Lei J, Ploner A, Elfström KM, et al.HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med,2021,76(1):1340-1348.
[23] Madleen O, Susanne KK, Christian D, et al.The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity[J]. Vaccine,2020,38(6):1345-1351.
[24] Folschweiller N, Behre U, Dionne M, et al.Long-term cross-reactivity against nonvaccine human papillomavirus types 31 and 45 after 2- or 3-dose schedules of the AS04-adjuvanted human HPV-16/18 vaccine[J]. J Infect Dis,2019,219(11):1799-1803.
[25] Aregay M, Shkedy Z, Molenberghs G, et al.Model-based estimates of long-term persistence of induced HPV antibodies: A flexible subject-specific approach[J]. J Biopharm Stat,2013,23(6):1228-1248.
[26] David MP, Van Herck K, Hardt K, et al.Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses[J]. Gynecol Oncol,2009,115(3 Suppl):S1-S6.
[27] Ferris DG, Samakoses R, Block SL, et al.4-Valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years[J]. Pediatrics,2017,140(6): e20163947.
[28] Toh ZQ.Evaluation of long-term immunological responses following reduced-dose quadrivalent human papillomavirus vaccine schedules in Fiji[D]. Australia:University of Melbourne,2017.
[29] Olsson SE, Restrepo JA, Reina JC, et al.Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up[J]. Papillomavirus Res,2020,10:100203.
[30] Bornstein J, Roux S, Kjeld PL, et al.Three-year follow-up of 2-dose versus 3-dose HPV vaccine[J]. Pediatrics,2021,147(1): e20194035.
[31] Einstein MH, Levin MJ, Chatterjee A, et al.Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through month 48 in a phase III randomized study[J]. Hum Vaccin Immunother,2014,10(12):3455-3465.
[32] Reiter PL, Brewer NT, Gottlieb SL, et al.How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen[J]. Vaccine,2009,27(49):6840-6844.
[33] Joura EA, Giuliano AR, Iversen OE, et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med,2015,372(8):711-723.
[34] 陈桂珍. 由大肠杆菌制备的人乳头瘤病毒(16型和18型)二价疫苗的免疫原性和安全性:Ⅱ期临床试验[J]. 微生物学免疫学进展,2016,44(5):85.
[35] CDC. HPV vaccine safety[EB/OL].(2021-07-23)[2021-09-09].https://www.cdc.gov/vaccinesafety/vaccines/hpv/hpv-safety-faqs.html,2020.
[36] Tiffany AS, Paige L, Jorge A, et al.Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017[J]. Br J Clin Pharmacol,2018,84(12): 2928-2932.
[37] Jorge EA, Theresa H, Maria C, et al.Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015[J]. Vaccine,2018,36(13): 1781-1788.
[38] Phillips A, Patel C, Pillsbury A, et al.Safety of human papillomavirus vaccines: An updated review[J]. Drug Saf,2018,41(4):329-346.
[39] 乔友林,吴婷,李荣成,等. 双价人乳头瘤病毒疫苗(大肠杆菌)的有效性研究:一项随机对照临床试验的中期分析[J]. 中国妇产科临床杂志,2020,21(6):581-584.
[40] Edson DM, Stan LB, Daron F, et al.Safety profile of the 9-valent HPV vaccine: A combined analysis of 7 phase III clinical trials[J]. Pediatrics,2016,138(2):1-17.
[41] Vesikari T, Brodszki N, van Damme P, et al. A randomized, double-blind, phase iii study of the immunogenicity and safety of a 9-valent human papillomavirus l1 virus-like particle vaccine (V503) versus Gardasil® in 9-15-year-old girls[J]. Pediatr Infect Dis J,2015,34(9):992-998.
[42] No authors listed.Meeting of the global advisory committee on vaccine safety, 7-8 June 2017[J]. Wkly Epidemiol Rec,2017,92(28):393-402.
[43] Ojha RP, Jackson BE, Tota JE, et al.Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States[J]. Hum Vaccin Immunother,2014,10(1):232-237.
[44] Miranda S, Chaignot C, Collin C, et al.Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France[J]. Vaccine,2017,35(36):4761-4768.
[45] Vielot NA, Becker-Dreps S.Hazard of complex regional pain syndrome following human papillomavirus vaccination among adolescent girls in the United States: A case-cohort analysis of insurance claims data[J]. Expert Opin Drug Saf,2020,19(1):107-112.
[46] 汪安石,黄演林,刘畅,等. (围)妊娠期HPV疫苗接种对后代出生缺陷发生风险的影响[J]. 中国产前诊断杂志(电子版),2020,12(3):34-39.
[47] 赖婷,王艳萍,李小洪,等. 预防性接种人乳头瘤病毒疫苗对妊娠结局的影响[J]. 中华妇幼临床医学杂志(电子版),2018,14(6):621-628.
[48] 郭建铭,郑斌,李娜,等. 人乳头瘤病毒疫苗预防中国女性宫颈癌药物经济学研究的系统评价[J]. 中国现代应用药学,2021,38(4):445-452.
[49] European Medicines Agency.Assessment report cervarix[EB/OL].(2013-01-01)[2021-09-09].https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix,2013.
[50] Aljunid S, Maimaiti N, Nur AM, et al.Cost-effectiveness of HPV vaccination regime:Comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia[J]. BMC Public Health,2016,16:71.
[51] Prinja S, Bahuguna P, Faujdar DS, et al.Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program[J]. Cancer,2017,123(17):3253-3260.
[52] Phua LC, Choi H, Wu J, et al.Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore[J]. Vaccine,2021,39(16):2255-2263.
[53] Mahumud RA, Gow J, Alam K, et al.Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh[J]. Vaccine,2020,38(2):165-172.
[54] Mennini FS, Bonanni P, Bianic F, et al.Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy[J]. Cost Eff Resour Alloc,2017,15:11.
[55] Zou Z, Fairley CK, Ong JJ, et al.Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: A cost-effectiveness analysis[J]. Lancet Glob Health,2020,8(10):e1335-e1344.
[56] 徐小倩,由婷婷,胡尚英,等. 全球人乳头瘤病毒疫苗接种指南制定现状的系统综述[J]. 中华医学杂志,2021,101(24):1890-1898.
[57] WHO.Vaccine in national immunization program update[R]. Geneva:WHO:2020.
[58] Bruni L, Saura A, Montoliu A, et al.HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019[J]. Prev Med,2020,144:106399.
[59] 冯雪娇,侯海龙,喻琼,等. 我国宫颈癌疫苗市场分析及对策研究[J]. 中国生物工程杂志,2020,40(11):96-101.
[60] 史金晶,张肖肖,郑徽,等. 中国大陆青少年家长人乳头瘤病毒疫苗认知度和接受度Meta分析[J]. 中国疫苗和免疫,2019,25(4):464-470.
[61] Mcclymont E, Lee M, Raboud J, et al.The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus[J]. Clin Infect Dis,2019,68(5):788-794.
[62] Macintyre CR, Shaw PJ, Mackie FE, et al.Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children[J]. Vaccine,2019,37(37):5630-5636.
[63] Ingrid HRG, Natalia FP, Aline L, et al.Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: A real-world interventional multi-centre study[J]. Lupus,2020,29(8): 096120332092840.
[64] Praditpornsilpa K, Kingwatanakul P, Deekajorndej T, et al.Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD[J]. Nephrol Dial Transplant,2017,32(1):132-136.